Billy Rosson, MD
Pulmonary Disease · Lafayette, LANPI 1164414629
Payments from drug & device makers
Across 615 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Sanofi$895
- Regeneron Healthcare Solutions, Inc.$808
- Boehringer Ingelheim$652
- Insmed, Inc.$461
- plus $3K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 231 | $3,336 |
| AstraZeneca | 80 | $1,526 |
| Sanofi | 32 | $895 |
| Regeneron Healthcare Solutions, Inc. | 29 | $808 |
| Boehringer Ingelheim | 34 | $652 |
| Insmed, Inc. | 31 | $461 |
| Grifols USA, LLC | 22 | $441 |
| Mylan Specialty L.p. | 18 | $375 |
| Actelion Pharmaceuticals US, Inc. | 13 | $352 |
| Amgen | 11 | $203 |
| Mallinckrodt Hospital Products Inc. | 9 | $197 |
| Genentech USA, Inc. | 10 | $195 |
| Novartis | 11 | $193 |
| E.r. Squibb & Sons, L.L.C. | 11 | $162 |
| Merck | 7 | $156 |
| Bayer | 8 | $139 |
| United Therapeutics Corporation | 8 | $137 |
| Intuitive Surgical | 1 | $124 |
| Gilead | 8 | $120 |
| Electromed, Inc. | 8 | $71 |
| Verona Pharma, Inc. | 3 | $68 |
| Viatris Specialty LLC | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 4 | $65 |
| ANI Pharmaceuticals, Inc. | 2 | $60 |
| Johnson & Johnson | 4 | $56 |
| AbbVie | 3 | $46 |
| Astellas Pharma US Inc | 2 | $34 |
| Philips North America LLC | 2 | $32 |
| Circassia Inc. | 2 | $28 |
| Liquidia Technologies, Inc. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Acacia Pharma Inc | 1 | $20 |
| Pulmonx Corporation | 1 | $20 |
| UCB, Inc. | 1 | $20 |
| Livanova USA, Inc. | 1 | $15 |
| Fisher & Paykel Healthcare Inc | 1 | $15 |
| EKOS Corporation | 1 | $12 |
How this compares
$11,144 in reported general payments places this provider in the 65th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Lafayette
- Frank CourmierLafayette$15K
- Timothy KeysLafayette$14K
- Walter BrownLafayette$12K
- David GreenShreveport$2M
- Joseph LaskyNew Orleans$1.9M
- Leonardo SeoaneNew Orleans$1.6M
- Ross KlingsbergNew Orleans$1.2M
- Juzar AliNew Orleans$775K
- Hollis O NealBaton Rouge$682K
- Andrea EspinozaHouma$655K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.